Inclusion Criteria:

- Patients who were diagnosed by the histologic, cytologic diagnosis of IIIB (malignant
hydrothorax or hydropericardium) or IV non-small cell lung cancer

- ≥ 18 years old

- patients who have received more than one regimen of platinum-based chemotherapy;
patients who have received EGFR monoclonal treatment could also be enrolled

- At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and
can be measured by imaging tools

- have an interval of more than 4 weeks from the last chemo- or radio-therapy; 2 weeks
from the last targeted therapy

- ECOG 0-2

- Expected life time longer than 3 months

- Normal laboratory values:

- leucocyte≥ 4×109/L

- neutrophil≥ 1.5×109/L

- platelet≥90×109/L

- Hemoglobin≥ 9g/L

- ALT and AST ≤3×ULN (≤5×ULN if liver metastasis)

- serum creatinine<1.5 mg/dl

- bilirubin <1.5×ULN

- No allergy to biological drug

- Sign the consent forms

Exclusion Criteria:

- Patients who have previously received Docetaxel or anti-VEGF inhibitors

- Severe symptomatic heart disease

- Female patients during their pregnant and lactation period, or patients without
contraception

- Severe uncontrolled infection

- Uncontrolled neurologic or psychiatric disease; Uncontrolled primary or metastatic
brain tumor

- Patients with other malignant tumor,except for basal cell carcinoma,squamous cell
carcinoma and carcinoma in situ

- Patients have accepted other clinical trials